撞擊區塊鏈（BFI）與CSIR-CDRI簽署了協議，以加強生物醫學研究並推動醫療保健創新

該合作是在BFI-BIOME虛擬網絡計劃下的，該計劃旨在滿足該國未滿足的臨床需求

Blockchain For Impact (BFI), a healthcare fund established during the second wave of the COVID-19 pandemic in India, has signed an agreement with CSIR-Central Drug Research Institute (CDRI) to bolster biomedical research and drive innovation in healthcare.

Impact Block鏈（BFI）是在印度第二次COVID-19大流行期間建立的醫療基金，已與CSIR-中心藥物研究所（CDRI）簽署了一項協議，以增強生物醫學研究並推動醫療保健的創新。

The collaboration falls under the BFI-BIOME Virtual Network Program, which aims to address unmet clinical needs in the country, focusing on research in malaria, dengue, and metabolic diseases. The partnership seeks to forge new pathways for translational research that will shape the future of healthcare and revolutionize India's public health landscape.

該協作屬於BFI-BIOME虛擬網絡計劃，該計劃旨在滿足該國未滿足的臨床需求，重點關注瘧疾，登革熱和代謝疾病的研究。該合作夥伴關係旨在為轉化研究奠定新的途徑，以塑造醫療保健的未來並徹底改變印度的公共衛生景觀。

BFI, a catalyst funder within the global blockchain industry, works with partners to build multi-sector collaborations that create long-term, equitable solutions to strengthen India's strained healthcare infrastructure and support marginalized and vulnerable communities.

BFI是全球區塊鏈行業中的催化劑資助者，與合作夥伴合作，建立多部門的合作，創建長期，公平的解決方案，以加強印度緊張的醫療保健基礎設施，並支持邊緣化和脆弱的社區。

BFI has also announced a partnership with the Translational Health Science and Technology Institute (THSTI) under the BFI-BIOME Virtual Network Program to accelerate translational research in vaccines, infectious diseases, diagnostics, and metabolic diseases. BFI said the collaboration aligns with the nation's Viksit Bharat (developed India) goal by 2047 and contributes to India's vision of becoming a global leader in biotechnology.

BFI還宣布了與BFI-BIOME虛擬網絡計劃下的轉化健康科學技術研究所（THSTI）合作，以加速疫苗，傳染病，診斷和代謝疾病的轉化研究。 BFI表示，該合作與美國維克西特·巴拉特（Viksit Bharat）（開發的印度）到2047年的目標保持一致，並為印度成為生物技術的全球領導者的願景做出了貢獻。

BFI has been actively working with leading Indian institutions to drive advancements in healthcare in the world's most populous country. In 2024, it allocated over $150,000 over three years to support healthcare-focused startup initiatives at the Indian Institute of Technology Kanpur (IITK), renowned for its excellence in science and engineering education. This cooperation aims to develop innovative solutions to address critical challenges within India's healthcare system.

BFI一直在與領先的印度機構積極合作，以推動世界上人口最多的國家的醫療保健發展。 2024年，它在三年內分配了15萬美元，以支持印度坎普爾理工學院（IITK）以醫療保健為中心的初創企業計劃，以其在科學和工程教育方面的卓越表現而聞名。這種合作旨在開發創新的解決方案，以應對印度醫療保健系統內的關鍵挑戰。

Moreover, BFI has committed $900,000 over three years to the Indian Institute of Technology Bombay, a leading institution in engineering and research, to accelerate biomedical research across the country. Furthermore, it partnered with the Indian Institute of Science (IISc) to fund select life sciences research projects led by IISc faculty, fostering further innovation in the field.

此外，BFI在三年內向印度技術研究所（Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Engineering and Research是一家領先的機構，以加速全國的生物醫學研究。此外，它與印度科學學院（IISC）合作，為由IISC教師領導的精選生命科學研究項目提供資金，從而促進了該領域的進一步創新。

India's healthcare sector has been leading the way in adopting emerging technologies, like blockchain and artificial intelligence (AI), to improve patient care, streamline operations, and strengthen data security. Despite these advancements, managing patient data securely and efficiently remains a significant hurdle. Blockchain technology presents a promising solution, providing a secure and transparent platform for data management that helps prevent breaches by creating an immutable record.

印度的醫療保健部門一直在採用區塊鍊和人工智能（AI）等新興技術，以改善患者護理，簡化操作並加強數據安全。儘管取得了這些進步，但可以安全有效地管理患者數據仍然是一個重大障礙。區塊鏈技術提出了一個有希望的解決方案，為數據管理提供了一個安全透明的平台，該平台有助於通過創建不變的記錄來防止違規。

Moreover, blockchain can facilitate seamless data sharing between pharmaceutical companies and researchers, enhancing the development of new therapies and treatments.

此外，區塊鏈可以促進製藥公司和研究人員之間的無縫數據共享，從而增強新療法和治療方法的發展。

In addition to strengthening data security, blockchain can facilitate seamless data exchange between pharmaceutical companies and researchers, accelerating the discovery of new therapies and treatments.

除了加強數據安全外，區塊鏈還可以促進製藥公司與研究人員之間的無縫數據交換，從而加快發現新療法和治療方法。

According to a report by PwC, the Bengal Chamber, and Medica Hospitals, “Globally, healthcare organizations have started reaping the benefits of blockchain technology in terms of its various applications, such as in health data management, health information exchange, provider credentialing and accreditation, and pharmaceutical supply chain management.”

根據普華永道，孟加拉商會和醫療醫院的報告，“全球醫療機構已經開始在其各種應用方面收穫區塊鏈技術的好處和藥品供應鏈管理。”

“[The] Adoption of blockchain technology by the Indian healthcare industry will happen over a period of time as the effectiveness and sustainability of each use case are currently under research and development. At the same time, healthcare organizations need to undertake the necessary planning activities before entering into blockchain-based partnerships and programs,” the report said.

“由於目前正在研究和開發中，印度醫療保健行業對區塊鏈技術的採用將在一段時間內發生。同時，醫療組織需要在建立基於區塊鏈的合作夥伴關係和計劃之前進行必要的計劃活動。”

India plans Bio-Artificial Intelligence hubs

印度計劃生物界情報樞紐

India recently introduced the BioE3 (Biotechnology for Economy, Employment, and Environment) Policy, marking a significant milestone for the local biotechnology sector and reinforcing its potential to shape the economy, employment landscape, and environmental sustainability in the years to come.

印度最近引入了BIOE3（用於經濟，就業和環境的生物技術）政策，標誌著當地生物技術部門的重要里程碑，並增強了其在未來幾年塑造經濟，就業環境和環境可持續性的潛力。

The objective of the BioE3 Policy is to set forth a framework that ensures the adoption of cutting-edge advanced technologies and aligns innovative research to promote biomanufacturing.

BIOE3政策的目的是製定一個框架，以確保採用尖端的先進技術並結盟創新的研究以促進生物製造。

Biomanufacturing is closely tied to healthcare, as it leverages living organisms like cells and microorganisms to produce therapeutic drugs, vaccines, and diagnostic tools. This process is crucial in developing modern medical treatments, including monoclonal antibodies, proteins, and cell-based therapies, and plays a vital role in advancing healthcare through personalized medicine and targeted treatments.

生物製造與醫療保健密切相關，因為它利用細胞和微生物等生物體生產治療藥物，疫苗和診斷工具。該過程對於開發現代醫療治療至關重要，包括單克隆抗體，蛋白質和基於細胞的療法，並且在通過個性化醫學和有針對性治療的醫療保健方面起著至關重要的作用。

India's BioE3 Policy aims to accelerate the development of technologies for bio-based products and their commercialization by setting up BioEnablers, including Bio-Artificial Intelligence (bio-AI) hubs, foundries, and biomanufacturing hubs across the country.

印度的BIOE3政策旨在通過建立包括生物兵工智能（Bio-AI）樞紐，鑄造廠和生物製造樞紐在內的生物啟程器來加速基於生物產品的技術及其商業化的技術。

Bio-AI hubs will be set up to augment research and innovation for developing technologies for bio-based products across the identified thematic sectors and subsectors of biomanufacturing by powering data-driven research and AI-informed predictive analytics. The bio-foundries and biomanufacturing hubs will focus on establishing infrastructure to scale up technologies for bio-based products.

Bio-AI樞紐將通過為確定的主題扇區和生物製造的亞部門開發基於生物的產品的技術的研究和創新，通過為數據驅動的研究和AI知識的預測分析提供動力。生物基礎和生物製造樞紐將著重於建立基礎設施，以擴展基於生物的產品的技術。

According to Science and Technology Minister Jitendra Singh, India is among the top six bio-manufacturers in the world and has one of the most cost-effective and efficacy-based biomanufacturing and healthcare destinations.

根據科學和技術部長吉滕德拉·辛格（Jitendra Singh）的說法，印度是世界上六名生物製造商之一，並且是最具成本效率和基於功效的生物製造和醫療保健目的地之一。

“Prime Minister Narendra Modi has a vision for a healthy India with the elimination of communicable diseases and reduction in non

“總理納倫德拉·莫迪（Narendra Modi